105 related articles for article (PubMed ID: 15166625)
1. Prolonged schedule of temozolomide (Temodal) plus liposomal doxorubicin (Caelyx) in advanced solid cancers.
Awada A; Gil T; Sales F; Dubuisson M; Vereecken P; Klastersky J; Moerman C; de Valeriola D; Piccart MJ
Anticancer Drugs; 2004 Jun; 15(5):499-502. PubMed ID: 15166625
[TBL] [Abstract][Full Text] [Related]
2. Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumors.
Mavroudis D; Kouroussis Ch; Kakolyris S; Agelaki S; Kalbakis K; Androulakis N; Souglakos J; Samonis G; Georgoulias V
Oncology; 2002; 62(3):216-22. PubMed ID: 12065868
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme.
Chua SL; Rosenthal MA; Wong SS; Ashley DM; Woods AM; Dowling A; Cher LM
Neuro Oncol; 2004 Jan; 6(1):38-43. PubMed ID: 14769139
[TBL] [Abstract][Full Text] [Related]
5. Phase I. Trial of irinotecan and temozolomide in patients with solid tumors.
Jones SF; Gian VG; Greco FA; Miranda FT; Shipley DL; Thompson DS; Hainsworth JD; Toomey MA; Willcutt NT; Burris HA
Oncology (Williston Park); 2003 May; 17(5 Suppl 5):41-5. PubMed ID: 12800606
[TBL] [Abstract][Full Text] [Related]
6. Treatment-related toxicities in tumor-bearing cats treated with temozolomide alone or in combination with doxorubicin: a pilot assessment.
Gagnon J; Dervisis NG; Kitchell BE
J Feline Med Surg; 2012 Aug; 14(8):560-5. PubMed ID: 22496148
[TBL] [Abstract][Full Text] [Related]
7. Dose-dense regimen of temozolomide given every other week in patients with primary central nervous system tumors.
Vera K; Djafari L; Faivre S; Guillamo JS; Djazouli K; Osorio M; Parker F; Cioloca C; Abdulkarim B; Armand JP; Raymond E
Ann Oncol; 2004 Jan; 15(1):161-71. PubMed ID: 14679137
[TBL] [Abstract][Full Text] [Related]
8. A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies.
Britten CD; Rowinsky EK; Baker SD; Agarwala SS; Eckardt JR; Barrington R; Diab SG; Hammond LA; Johnson T; Villalona-Calero M; Fraass U; Statkevich P; Von Hoff DD; Eckhardt SG
Clin Cancer Res; 1999 Jul; 5(7):1629-37. PubMed ID: 10430061
[TBL] [Abstract][Full Text] [Related]
9. Phase I study of pegylated liposomal doxorubicin (Caelyx) in combination with carboplatin in patients with advanced solid tumors.
Gonçalves A; Braud AC; Viret F; Genre D; Gravis G; Tarpin C; Giovannini M; Maraninchi D; Viens P
Anticancer Res; 2003; 23(4):3543-8. PubMed ID: 12926104
[TBL] [Abstract][Full Text] [Related]
10. A phase I and pharmacokinetic study of irofulven and capecitabine administered every 2 weeks in patients with advanced solid tumors.
Alexandre J; Kahatt C; Bertheault-Cvitkovic F; Faivre S; Shibata S; Hilgers W; Goldwasser F; Lokiec F; Raymond E; Weems G; Shah A; MacDonald JR; Cvitkovic E
Invest New Drugs; 2007 Oct; 25(5):453-62. PubMed ID: 17628744
[TBL] [Abstract][Full Text] [Related]
11. Phase I dose escalation study of pegylated liposomal doxorubicin (Caelyx) in combination with topotecan in patients with advanced malignancies.
Ghesquières H; Faivre S; Djafari L; Pautier P; Lhommé C; Lozahic S; Djazouli K; Armand JP; Raymond E
Invest New Drugs; 2006 Sep; 24(5):413-21. PubMed ID: 16763786
[TBL] [Abstract][Full Text] [Related]
12. Randomized phase II study of temozolomide given every 8 hours or daily with either interferon alfa-2b or thalidomide in metastatic malignant melanoma.
Danson S; Lorigan P; Arance A; Clamp A; Ranson M; Hodgetts J; Lomax L; Ashcroft L; Thatcher N; Middleton MR
J Clin Oncol; 2003 Jul; 21(13):2551-7. PubMed ID: 12829675
[TBL] [Abstract][Full Text] [Related]
13. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
Hong DS; Kurzrock R; Falchook GS; Andresen C; Kwak J; Ren M; Xu L; George GC; Kim KB; Nguyen LM; O'Brien JP; Nemunaitis J
Oncotarget; 2015 Dec; 6(40):43127-34. PubMed ID: 26503473
[TBL] [Abstract][Full Text] [Related]
14. A phase I and pharmacokinetic study of irofulven and cisplatin administered in a 30-min infusion every two weeks to patients with advanced solid tumors.
Hilgers W; Faivre S; Chieze S; Alexandre J; Lokiec F; Goldwasser F; Raymond E; Kahatt C; Taamma A; Weems G; MacDonald JR; Misset JL; Cvitkovic E
Invest New Drugs; 2006 Jul; 24(4):311-9. PubMed ID: 16683074
[TBL] [Abstract][Full Text] [Related]
15. Phase I trial of weekly docetaxel and daily temozolomide in patients with metastatic disease.
Tamaskar I; Mekhail T; Dreicer R; Olencki T; Roman S; Elson P; Bukowski RM
Invest New Drugs; 2008 Dec; 26(6):553-9. PubMed ID: 18626572
[TBL] [Abstract][Full Text] [Related]
16. A randomized phase I and pharmacological trial of sequences of 1,3-bis(2-chloroethyl)-1-nitrosourea and temozolomide in patients with advanced solid neoplasms.
Hammond LA; Eckardt JR; Kuhn JG; Gerson SL; Johnson T; Smith L; Drengler RL; Campbell E; Weiss GR; Von Hoff DD; Rowinsky EK
Clin Cancer Res; 2004 Mar; 10(5):1645-56. PubMed ID: 15014015
[TBL] [Abstract][Full Text] [Related]
17. Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG).
Toma S; Tucci A; Villani G; Carteni G; Spadini N; Palumbo R
Anticancer Res; 2000; 20(1B):485-91. PubMed ID: 10769710
[TBL] [Abstract][Full Text] [Related]
18. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
19. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
20. Temozolomide: the effect of once- and twice-a-day dosing on tumor tissue levels of the DNA repair protein O(6)-alkylguanine-DNA-alkyltransferase.
Spiro TP; Liu L; Majka S; Haaga J; Willson JK; Gerson SL
Clin Cancer Res; 2001 Aug; 7(8):2309-17. PubMed ID: 11489806
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
